What happened with AARD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Aardvark Therapeutics focuses on ARD-101, an experimental drug for the excessive hunger associated with Prader-Willi syndrome, a rare disease. Its approach targets pathways linked to hunger, but has not been proven to treat hunger-related conditions.
The company currently funds its work mainly by selling equity rather than earning money from customers. Future product sales depend on completing clinical development and obtaining regulatory approval; payment would then depend on insurance coverage and reimbursement or patients’ willingness to pay. Aardvark uses outside companies to manufacture its drugs and handle clinical supplies rather than operating its own factories.
The business depends primarily on ARD-101. In February 2026, Aardvark voluntarily paused enrollment and dosing in its Phase 3 HERO trial and related studies after reversible cardiac observations in a healthy-volunteer study. It was reviewing the findings with the FDA to determine next steps. Continuing development also requires additional funding.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Aardvark’s prospects hinge on ARD-101’s clinical results and approval, with Soleno Therapeutics’ approved VYKAT XR the key existing rival for excessive hunger in Prader-Willi syndrome (PWS).
Rhythm Pharmaceuticals already markets IMCIVREE for specified forms of rare genetic obesity and is developing treatments for excessive hunger that Aardvark identifies as rivals to ARD-101. Watch those hunger-treatment programs, rather than treating IMCIVREE’s existing approvals as approvals for PWS.
Relmada Therapeutics’ sepranolone and Aardvark’s ARD-101 seek the same PWS treatment opportunity, with neither company yet selling an approved product. Sepranolone is described as ready for Phase 2b; its PWS development progress is more relevant to Aardvark than Relmada’s lead bladder-cancer program.
Bright Minds Biosciences is developing BMB-101 and BMB-105 for PWS, putting both alongside Aardvark’s ARD-101 in the race to treat these patients. Watch preparations for BMB-101’s Phase 2 PWS trial and BMB-105’s work toward permission to begin human trials, rather than BMB-101’s ongoing epilepsy trials.
Harmony Biosciences’ Phase III pitolisant program targets the same PWS patient population as Aardvark, although that overlap does not establish that the drugs treat the same symptoms. Harmony already sells pitolisant as WAKIX through specialty distributors; its PWS trial news is the closer signal for Aardvark.
Novo Nordisk’s marketed Wegovy and Saxenda compete in the broader obesity market Aardvark’s weight-loss programs seek to enter, rather than directly matching its PWS focus. Their efficacy, tolerability and payer coverage matter to how competitive a future Aardvark weight-loss treatment could be.
Eli Lilly’s marketed Zepbound competes for the broader obesity patients Aardvark’s weight-loss programs seek to treat, setting an efficacy and commercial benchmark. Watch Zepbound’s weight-loss performance, tolerability and payer coverage when judging what Aardvark would need to offer.
Viking Therapeutics and Aardvark are developing drugs that would compete for weight-management patients, while Aardvark’s PWS program serves a more specialized group. Neither has generated product revenue, so Viking’s obesity-development progress—not current drug sales—is the relevant comparison.
Kailera Therapeutics’ weekly injectable ribupatide competes with Aardvark’s broader weight-loss efforts, not directly with its specialized PWS focus. Its global Phase 3 obesity trials expect topline results in 2028, a concrete readout to watch for the broader competitive field Aardvark would enter.
Fed Interest Rate Decision
For Aardvark Therapeutics, the Fed’s decision on its benchmark interest rate matters because it can change the interest earned as the company reinvests its $110 million in cash and short-term investments, as well as the cost of any borrowing.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift interest earned as Aardvark reinvests its cash, adding to other income, while raising the cost if it needs to borrow to fund its research and trials.
If it comes in below expectations
Lower rates can reduce interest earned as Aardvark reinvests its cash, weighing on other income, while making borrowing cheaper if it needs funding for research and trials.
Eli Lilly & Co. earningsLLY
Lilly’s report will show how Zepbound is selling and gaining payer coverage, a commercial benchmark for Aardvark’s potential weight-loss treatments.
Look for Lilly’s account of Zepbound sales, patient uptake and payer coverage. Strong sales and broadening coverage would show that Aardvark’s broader weight-loss efforts would face an established commercial option; constrained sales or access would soften that benchmark, but would not prove demand for Aardvark’s candidates. Zepbound serves the broader obesity market, not a direct comparison for Aardvark’s Prader-Willi syndrome program.
Rhythm Pharmaceuticals, Inc. earningsRYTM
Rhythm Pharmaceuticals’ report may show whether its excessive-hunger programs are advancing, a signal of the competitive field facing Aardvark’s ARD-101.
Compare progress in Rhythm’s excessive-hunger treatment candidates with the status of Aardvark’s ARD-101 trials. Advancement would show that competition for these patients is moving forward; delays or setbacks would weaken the evidence of a near-term rival, but would not show that ARD-101 works or will be approved. Keep Rhythm’s marketed IMCIVREE separate from these programs: its approvals for specified forms of genetic obesity are not approval to treat Prader-Willi syndrome.
Aardvark Therapeutics, Inc. earningsThis company
Aardvark Therapeutics has no product sales, so this report will show whether its cash use and ARD-101 trial progress leave room to keep developing the drug.
Read operating cash use alongside the cash balance, then consider research and development spending and any update on the ARD-101 trials. Lower cash use, resources to keep development moving and a clearer path through the trial review would leave the company more room to proceed; continued rapid cash use without trial progress would shorten its runway and could bring financing or changes to development closer. Lower research spending could simply reflect paused trials, not a resolution of the safety issue.
